...
首页> 外文期刊>Journal of neurosurgery. >Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function.
【24h】

Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function.

机译:伽玛刀对垂体腺瘤的放射手术对垂体功能的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECT: The authors undertook a retrospective analysis of the incidence and time course of pituitary insufficiency following gamma knife radiosurgery (GKS) for pituitary adenomas. METHODS: Pituitary adenomas in 92 patients were analyzed. There were 61 hormonally inactive tumors, 18 prolactinomas, and nine somatotropic and four adrenocorticotropic adenomas. The mean tumor volume was 3.8 cm3 (range 0.2-14.6 cm3). The mean prescription dose was 15 Gy. The mean prescription isodose was 50.7%. The mean follow-up time was 4.6 years (range 1.2-10 years). The following new or deteriorating insufficiencies that did not require treatment were recorded for the different pituitary axes: follicle-stimulating hormone (FSH)/ luteinizing hormone (LH) 19 (20.6%), thyroid-stimulating hormone (TSH) 32 (34.8%), adrenocorticotropic hormone (ACTH) 10 (10.9%), and growth hormone (GH) 26 (28.3%). For new insufficiencies or deterioration requiring replacement therapy, the figures were as follows: FSH/LH 20 (21.7%), TSH 22 (23.9%), ACTH eight (8.7%), and GH 12 (13%). Spot dosimetry was performed in 59 patients in the hypothalamic region, the pituitary gland, and pituitary stalk. The pituitary stalks in patients with deterioration of pituitary function received a statistically higher dosage of radiation, 7.7 +/- 3.7 Gy compared with 5.5 +/- 3 Gy (p = 0.03). CONCLUSIONS: The function of the residual normal pituitary gland is less affected following GKS of pituitary adenomas than after fractionated radiotherapy. Nonetheless, increased attention needs to be exercised to reduce the dose to the stalk and pituitary gland to minimize the incidence of these complications.
机译:目的:作者对伽玛刀治疗垂体腺瘤后垂体功能不全的发生率和时程进行了回顾性分析。方法:对92例垂体腺瘤进行分析。有61例无激素活动的肿瘤,18例泌乳素瘤,9个生长激素和4个促肾上腺皮质腺瘤。平均肿瘤体积为3.8 cm3(范围为0.2-14.6 cm3)。平均处方剂量为15 Gy。平均处方等剂量剂量为50.7%。平均随访时间为4.6年(范围1.2-10年)。对于不同的垂体轴,记录了以下不需要治疗的新的或恶化的功能不全:促卵泡激素(FSH)/促黄体激素(LH)19(20.6%),促甲状腺激素(TSH)32(34.8%) ,促肾上腺皮质激素(ACTH)10(10.9%)和生长激素(GH)26(28.3%)。对于需要替代疗法的新功能不全或恶化,数字如下:FSH / LH 20(21.7%),TSH 22(23.9%),ACTH 8(8.7%)和GH 12(13%)。对下丘脑区,垂体和垂体柄的59例患者进行了点剂量测定。垂体功能恶化的患者的垂体柄接受统计学上较高的放射剂量,为7.7 +/- 3.7 Gy,高于5.5 +/- 3 Gy(p = 0.03)。结论:垂体腺瘤GKS治疗后残留的正常垂体腺的功能比分次放疗后受到的影响小。但是,需要增加注意力以减少茎和垂体的剂量,以最大程度地减少这些并发症的发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号